Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Weighted Average and Diluted): 2010-2025

Historic EPS (Weighted Average and Diluted) for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $1.13.

  • Ani Pharmaceuticals' EPS (Weighted Average and Diluted) rose 188.98% to $1.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.63, marking a year-over-year increase of 385.96%. This contributed to the annual value of -$1.04 for FY2024, which is 222.35% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at $1.13 for Q3 2025, which was up 213.89% from $0.36 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $1.13 during Q3 2025, and its lowest value of -$1.87 during Q4 2021.
  • In the last 3 years, Ani Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of $0.29 in 2023 and averaged $0.17.
  • As far as peak fluctuations go, Ani Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 12,800.00% in 2022, and later surged by 1,266.67% in 2024.
  • Ani Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$1.87 in 2021, then skyrocketed by 84.49% to -$0.29 in 2022, then soared by 106.90% to $0.02 in 2023, then crashed by 2,850.00% to -$0.55 in 2024, then surged by 188.98% to $1.13 in 2025.
  • Its EPS (Weighted Average and Diluted) was $1.13 in Q3 2025, compared to $0.36 in Q2 2025 and $0.69 in Q1 2025.